Evidence map›Paper›PMID 28461764›Full record

ReviewPharmacogenomics and personalized medicine2017

ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches.

M C Cleophas, L A Joosten, L K Stamp, N Dalbeth, O M Woodward, Tony R Merriman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacogenomics and personalized medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. The Gut Microbiome in Hyperuricemia and Gout.Arthritis & rheumatology (Hoboken, N.J.) · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. The genetics of gout: translation into clinical practice.Therapeutic advances in musculoskeletal disease · 2025
    Review
  17. Article
  18. Article
  19. Association of theHeliyon · 2024
    Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 5 countries.

M C CleophasDepartment of Internal Medicine.
L A JoostenDepartment of Internal Medicine.
L K StampDepartment of Medicine, University of Otago Christchurch, Christchurch.
N DalbethDepartment of Medicine, University of Auckland, Auckland, New Zealand.
O M WoodwardDepartment of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Tony R MerrimanDepartment of Biochemistry, University of Otago, Dunedin, New Zealand.
University of Otago · NZRadboud Institute for Molecular Life Sciences · NLRadboud University Nijmegen · NLUniversity of Auckland · NZUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a result of the association of a common polymorphism (

Indexed as

ABCG2allopurinolBCRPgoutpolymorphismurateuric acid

Identifiers

PMID28461764
PMCPMC5404803
OpenAlexW2606194241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.